|Bid||230.00 x 200|
|Ask||260.00 x 900|
|Day's Range||234.05 - 242.99|
|52 Week Range||187.18 - 253.91|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||37.21|
|Earnings Date||Jan 29, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||0.68 (0.28%)|
|1y Target Est||266.07|
Does Thermo Fisher Scientific Inc. (NYSE:TMO) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions […]
The Zacks Analyst Blog Highlights: Alphabet, Bank of America, Tesla, Thermo Fisher and Carnival
In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.
Illumina’s gross profit grew from $482.0 million in the third quarter of 2017 to $597.0 million in the third quarter of 2018. Its gross margin expanded from 68.8% in the third quarter of 2017 to 71.16% in the third quarter of 2018 due to a higher share of consumables, which fetch higher margins on total revenue. For 2018 and 2019, Illumina’s gross margins are expected to be 70.16% and 70.33%, respectively, compared to its gross margin of 68.42% in 2017.
Illumina (ILMN) incurred an interest expense of $15.0 million in the third quarter of 2018 compared to $10.0 million in the previous year’s period. Illumina’s interest income grew from $4.0 million in the third quarter of 2017 to $14.0 million in the latest quarter. Its income tax provision increased from $23.0 million in the third quarter of 2017 to $44.0 million in the most recent quarter.
This increase was attributable to higher performance-based compensation and expenses to support the growth of Illumina’s operations. Its research and development expenses also increased from $134.0 million in the third quarter of 2017 to $159.0 million in the third quarter of 2018 due to an increased head count. For 2018 and 2019, Illumina is expected to incur research and development expenses of $599.5 million and $680.6 million, respectively.
Illumina (ILMN) generates revenue from the Americas, the EMEA (Europe, the Middle East, and Africa) region, Greater China, and the Asia-Pacific region. Its revenue from the Americas increased from $417.0 million in the third quarter of 2017 to $474.0 million in the third quarter of 2018. Its revenue in the EMEA region rose from $165.0 million in the third quarter of 2017 to $219.0 million in the third quarter of 2018.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture
Thermo Fisher Scientific (TMO) stock rose from $189.88 at the close of market on December 29, 2017, to $235.01 at the close of market on November 23, 2018, representing a rise of ~24% year-to-date. On November 23, Thermo Fisher Scientific stock closed the day at $235.01, a ~29% rise from its 52-week low of $181.51 on December 5, 2017. On November 8, Thermo Fisher Scientific declared a fourth-quarter cash dividend of $0.17 per share. It announced that it would pay the dividend on January 15, 2019, to shareholders on record at the close of market on December 17, 2018.
Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.
The big shareholder groups in Thermo Fisher Scientific Inc (NYSE:TMO) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease Read More...
In this daily bar chart of TMO, below, we can see that prices are still in an uptrend and above the rising 200-day moving average line. The daily On-Balance-Volume (OBV) line shows an uptrend until early October and then a small decline. Overall, the OBV line is positive but a decline below the late October low would give me some concern.
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Next year's revenue may not be so hot, but earnings should grow nicely as the company captures synergies and pays down debt.
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
WALTHAM, Mass. , Nov. 8, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend ...
WALTHAM, Mass. , Nov. 7, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected Jim Mullen to its board of directors. Mr. Mullen's ...
Strategas’ policy research director calls health care the midterms’ big winner—but he warns that Democrats could threaten profits if they try to roll back tax cuts.
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
Carter Worth, Cornerstone Macro, on quality bear-market stocks to buy. With CNBC's Joe Kernen and the Fast Money traders, Pete Najarian, Steve Grasso, Brian Kelly and Tim Seymour.